Right now, with the positive clinical trials results obtained so far with insulin, we can see the light at the end of the tunnel, and the increased valuation by many multiples with this platform technology being applied to other drugs. There are other companies trying to achieve the same goal as Generex - there are probably forty companies that I can find working on the same kinds of things. I like drug delivery companies better and I tell investors that risk is much less for those types of companies than biotech companies in general. Results can be seen and appreciated in a much faster time than with BioTech companies. BioTechs are slower because they usually have many variables, some of which they cannot control.
Clinical trials are usually longer - which many take many years to complete.
So in that instance I like this type of company as it provides a shorter term turnaround than the traditional BioTech companies. In the case of a drug delivery system, especially for insulin, it is shorter clinical trial because you have the patient information on the product and the product used or in the canister is, obviously, already approved. Therefore clinical trials are looking to compare efficacy versus the traditional the needle method of delivery. I think one to two years as an investment horizon for Generex to capitalize on the potential value of its oral insulin delivery system. We could expect the signings of major agreements in that time frame - and we will probably see a partnering of major significance within the short term period.